Morgan Grothaus
Family · Saint Louis, MONPI 1952842684
Payments from drug & device makers
Across 83 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$230
- Lilly USA, LLC$176
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
- Amgen$137
- Johnson & Johnson$123
- AstraZeneca$85
- plus $578 from 19 others
What the payments were for
- Food & beverage$1,468100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $230 |
| Lilly USA, LLC | 8 | $176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $139 |
| Amgen | 7 | $137 |
| Johnson & Johnson | 7 | $123 |
| AstraZeneca | 5 | $85 |
| Novartis | 6 | $82 |
| Pfizer | 4 | $77 |
| AbbVie | 4 | $61 |
| Abbott | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $26 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Bayer | 1 | $17 |
| Exact Sciences | 1 | $15 |
| GSK | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $13 |
| Organon | 1 | $9 |
How this compares
$1,468 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $45,918 |
| EliquisApixaban | 23 | $14,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,445 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 62 | $1,462 |
| Potassium Chloride | 13 | $1,407 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $921 |
| Gabapentin | 88 | $902 |
| Propranolol Hcl ErPropranolol Hcl | 14 | $747 |
| Duloxetine Hcl | 42 | $584 |
| Pregabalin | 20 | $574 |
| Cyclobenzaprine Hcl | 34 | $546 |
| Omeprazole | 55 | $506 |
| Escitalopram Oxalate | 53 | $458 |
| Levothyroxine Sodium | 69 | $418 |
| Montelukast Sodium | 41 | $416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230 | $45,91848 claims |
| PfizerEliquis | $77 | $14,75323 claims |
| GSKTrelegy Ellipta | $15 | $14,44522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,812 family providers in Missouri.
Other family in Saint Louis
- Rebecca SeabaughSaint Louis$68K
- Jordan PerezSaint Louis$43K
- Lindsay GwaltneySaint Louis$28K
- Sara WoottenSaint Louis$21K
- Kelly RobertsSaint Louis$17K
- Matthew CarySaint Louis$15K
- Philip DudakSaint Louis$14K
- Kenan SahbazSaint Louis$14K
- Nicole CarrSaint Louis$14K
- Ashley GarrettSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.